Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3′-deoxy-3′- 18F-fluorothymidine PET images in lung cancer

Journal of Nuclear Medicine

Volumn 54, Issue 9, 2013, Pages 1543-1550

  Thureau, Sébastien ^a   Chaumet Riffaud, Philippe ^b   Modzelewski, Romain ^a   Fernandez, Philippe ^c   Tessonnier, Laurent ^d   Vervueren, Laurent ^e   Cachin, Florent ^f   Berriolo Riedinger, Alina ^g   Olivier, Pierre ^h   Kolesnikov Gauthier, Hélène ⁱ   Blagosklonov, Oleg ^j   Bridji, Boumediene ^k   Devillers, Anne ^l   Collombier, Laurent ^m   Courbon, Fréderic ⁿ   Gremillet, Eric ^o   Houzard, Claire ^p   Marc Caignon, Jean ^q   Roux, Julie ^r   Aide, Nicolas ^s   Brenot Rossi, Isabelle ^t   Doyeux, Kaya ^a   Dubray, Bernard ^a   Vera, Pierre ^a   more..

^a UNIVERSITÉ DE ROUEN   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d Timone Academic Hospital   (France)

^e ANGERS UNIVERSITY HOSPITAL   (France)

^f Jean Perrin Cancer Center   (France)

^g Georges Francois Leclerc Cancer Center   (France)

^h UNIVERSITY HOSPITAL OF NANCY   (France)

ⁱ Oscar Lambret Cancer Center   (France)

^j UNIVERSITY HOSPITAL OF BESANÇON   (France)

^k CENTRE RENÉ GAUDUCHEAU   (France)

^l CENTRE EUGÈNE MARQUIS   (France)

^m NÎMES UNIVERSITY HOSPITAL   (France)

ⁿ CHU RANGUEIL   (France)

^o Nuclear Imaging Center   (France)

^p CENTRE HOSPITALIER LYON SUD   (France)

^q Centre Catherine de Sienne   (France)

^r GRENOBLE UNIVERSITY HOSPITAL   (France)

^s Francois Baclesse Cancer Institute   (France)

^t INSTITUT PAOLI CALMETTES   (France)

more..

Author keywords

Agreement; FDG; FLT; Lung cancer; PET

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3' FLUOROTHYMIDINE F 18; FLUORODEOXYGLUCOSE F 18; 1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; MISONIDAZOLE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DISTRIBUTION VOLUME; HUMAN; IMAGE ANALYSIS; LUNG NON SMALL CELL CANCER; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RADIATION DOSE DISTRIBUTION; RADIOACTIVITY; REPRODUCIBILITY; SCORING SYSTEM; TUMOR VOLUME; 18F-FMISO; ADULT; AGED; AGREEMENT; ALGORITHM; COMPARATIVE STUDY; COMPUTER ASSISTED DIAGNOSIS; CONTROLLED CLINICAL TRIAL; FDG; FEMALE; FLT; IMAGE ENHANCEMENT; LUNG CANCER; LUNG TUMOR; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; OBSERVER VARIATION; PET; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

18F-FMISO; AGREEMENT; FDG; FLT; LUNG CANCER; PET;

ADULT; AGED; ALGORITHMS; CARCINOMA, NON-SMALL-CELL LUNG; DIDEOXYNUCLEOSIDES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LUNG NEOPLASMS; MALE; MIDDLE AGED; MISONIDAZOLE; OBSERVER VARIATION; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR BURDEN;

EID: 84887336421     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.118083     Document Type: Article

References (39)

1. Bradley JD, Moughan J, Graham MV, et al. A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117. Int J Radiat Oncol Biol Phys. 2010;77:367-372.
2. De Ruysscher D, Faivre-Finn C, Nestle U, et al. European Organisation for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer. J Clin Oncol. 2010; 28:5301-5310.
3. Ung Y, Gu C, Cline K, et al. An Ontario Clinical Oncology Group (OCOG) randomized trial (PET START) of FDG PET/CT in patients with stage III nonsmall cell lung cancer (NSCLC): predictors of overall survival [abstract]. J Clin Oncol. 2011;29 (suppl):7018
4. Fleckenstein J, Hellwig D, Kremp S, et al. F-18-FDG-PET confined radiotherapy of locally advanced NSCLC with concomitant chemotherapy: results of the PET-PLAN pilot trial. Int J Radiat Oncol Biol Phys. 2011;81:e283- e289.
5. Nestle U, Kremp S, Schaefer-Schuler A, et al. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-small cell lung cancer. J Nucl Med. 2005;46:1342-1348.
6. Edet-Sanson A, Dubray B, Doyeux K, et al. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with nonsmall cell lung cancer (NSCLC). Radiother Oncol. 2012;102:251-257.
7. Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy: an international multi-center study. Radiother Oncol. 2005;77:18-24.
8. Choi W, Lee SW, Park SH, et al. Planning study for available dose of hypoxic tumor volume using fluorine-18-labeled fluoromisonidazole positron emission tomography for treatment of the head and neck cancer. Radiother Oncol. 2010; 97:176-182.
9. Hendrickson K, Phillips M, Smith W, Peterson L, Krohn K, Rajendran J. Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance. Radiother Oncol. 2011;101:369-375.
10. Han D, Yu J, Yu Y, et al. Comparison of 18F-fluorothymidine and 18F-fluorodeoxyglucose PET/CT in delineating gross tumor volume by optimal threshold in patients with squamous cell carcinoma of thoracic esophagus. Int J Radiat Oncol Biol Phys. 2010;76:1235-1241.
11. Roels S, Slagmolen P, Nuyts J, et al. Biological image-guided radiotherapy in rectal cancer: is there a role for FMISO or FLT, next to FDG? Acta Oncol. 2008; 47:1237-1248.
12. Lee NY, Mechalakos JG, Nehmeh S, et al. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys. 2008;70:2-13.
13. Vera P, Bohn P, Edet-Sanson A, et al. Simultaneous positron emission tomography (PET) assessment of metabolism with F-fluoro-2-deoxy-d-glucose (FDG), proliferation with F-fluoro-thymidine (FLT), and hypoxia with fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study. Radiother Oncol. 2011;98:109-116.
14. Hicks RJ, Rischin D, Fisher R, et al. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. Eur J Nucl Med Mol Imaging. 2005;32:1384-1391.
15. Rischin D, Hicks RJ, Fisher R, et al. Trans-Tasman Radiation Oncology Group Study 98.02. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol. 2006;24:2098-2104.
16. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960;20:37-46.
17. Fleiss JL, Lewin B, Paik MC. Statistical Methods for Rates and Proportions. Hoboken, NJ: John Wiley and Sons; 2003.
18. Byrt T, Bishop J, Carlin JB. Bias, prevalence and kappa. J Clin Epidemiol. 1993;46:423-429.
19. Feinstein AR, Cicchetti DV. High agreement but low kappa: I. The problems of Two Paradoxes. J Clin Epidemiol. 1990;43:543-549.
20. Palie O, Michel P, Ménard JF, et al. The predictive value of treatment response using FDG PET performed on day 21 of chemoradiotherapy in patients with oesophageal squamous cell carcinoma: a prospective, multicentre study (RTEP3). Eur J Nucl Med Mol Imaging. May 29, 2013 [Epub ahead of print].
21. Caldwell CB, Mah K, Ung YC, et al. Observer variation in contouring gross tumor volume in patients with poorly defined non-small-cell lung tumors on CT: the impact of 18FDG-hybrid PET fusion. Int J Radiat Oncol Biol Phys. 2001;51:923-931.
22. Steenbakkers RJ, Duppen JC, Fitton I, et al. Reduction of observer variation using matched CT-PET for lung cancer delineation: a three-dimensional analysis. Int J Radiat Oncol Biol Phys. 2006;64:435-448.
23. Aerts HJ, Bussink J, Oyen WJ, et al. Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: a prospective validation. Lung Cancer. 2012;75:73-76.
24. MacManus M, Nestle U, Rosenzweig KE, et al. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. Radiother Oncol. 2009;91:85-94.
25. Vauclin S, Doyeux K, Hapdey S, Edet-Sanson A, Vera P, Gardin I. Development of a generic thresholding algorithm for the delineation of 18FDG-PET-positive tissue: application to the comparison of three thresholding models. Phys Med Biol. 2009;54:6901-6916.
26. Hatt M, Cheze-le Rest C, van Baardwijk A, Lambin P, Pradier O, Visvikis D. Impact of tumor size and tracer uptake heterogeneity in 18F-FDG PET and CT non-small cell lung cancer tumor delineation. J Nucl Med. 2011;52:1690-1697.
27. Devic S, Tomic N, Faria S, Menard S, Lisbona R, Lehnert S. Defining radiotherapy target volumes using 18F-fluoro-deoxy-glucose positron emission tomography/ computed tomography: still a Pandora's box? Int J Radiat Oncol Biol Phys. 2010;78:1555-1562.
28. Hatt M, Visvikis D. Defining radiotherapy target volumes using 18F-fluoro-deoxy- glucose positron emission tomography/computed tomography: still a Pandora's box?: in regard to Devic et al. (Int J Radiat Oncol Biol Phys 2010).
29. Int J Radiat Oncol Biol Phys. 2010;78:1605.
30. Daisne JF, Duprez T, Weynand B, et al. Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology. 2004;233:93-100.
31. Nehmeh SA, Erdi YE, Ling CC, et al. Effect of respiratory gating on quantifying PET images of lung cancer. J Nucl Med. 2002;43:876-881.
32. Nehmeh SA, Erdi YE, Pan T, et al. Quantitation of respiratory motion during 4DPET/ CT acquisition. Med Phys. 2004;31:1333-1338.
33. Carlin S, Humm JL. PET of hypoxia: current and future perspectives. J Nucl Med. 2012;53:1171-1174.
34. Nehmeh SA, Lee NY, Schröder H, et al. Reproducibility of intratumor distribution of 18F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys. 2008;70:235-242.
35. Grosu AL, Souvatzoglou M, Röper B, et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;69:541-551.
36. Tian J, Yang X, Yu L, et al. A multicenter clinical trial on the diagnostic value of dual-tracer PET/CT in pulmonary lesions using 39-deoxy-39-18F-fluorothymidine and 18F-FDG. J Nucl Med. 2008;49:186-194.
37. Xu B, Guan Z, Liu C, et al. Can multimodality imaging using 18F-FDG/18F-FLT PET/CT benefit the diagnosis and management of patients with pulmonary lesions? Eur J Nucl Med Mol Imaging. 2011;38:285-292.
38. Gagel B, Piroth M, Pinkawa M, et al. pO polarography, contrast enhanced color duplex sonography (CDS), [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapyrelevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia? BMC Cancer. 2007;28;7:113.
39. Hatt M, Cheze le Rest C, Turzo A, Roux C, Visvikis D. A fuzzy locally adaptive Bayesian segmentation approach for volume determination in PET [letter]. IEEE Trans Med Imaging. 2009;28:881-893.